All good things must come to an end, as they did this Monday evening for the fifteen Support Group Leaders (SGLs) who attended American Society of Hematology (ASH) conference this year. For many, it was not the first time at ASH; however, there were two, as we call them, newbies. But as the weekend progressed, […]

There are only a few abstracts left to attend, and every one we listened to were excellent. Yesterday, the focus of our attendance was on advances in myeloma. Because I have an interest in educating myself about smoldering multiple myeloma (SMM), I was eager to hear the latest studies on this subject. Dr. Rajkumar’s presentation, […]

Well, I survived the first day and half here at ASH. This is my second time to attend, and the advances in treatment have been great since my last attendance. We have three new treatments approved in a matter of weeks: Darzalex (daratumumab), Ninalor (ixazomib), and Empliciti (elotuzumab) as well as more on the way. […]

As I prepare to attend ASH for a second time, so much flows through my mind. What new therapies will be discussed? What treatments are in clinical trials? How close are we to a cure? Twelve years ago, when my husband was diagnosed, thalidomide and dexamethasone were the standard of treatment. I wonder, “How far […]